SGHT · Sight Sciences, Inc.
$8.14
-0.18 (-2.16%)
At close · Aug 14
Market Cap
$448.42M
Shares
55.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.14
Open$8.34
Day$8.09–8.47
52W close$3.20–9.05
Avg vol 30d242K
Short int827K · 1.5% float · 5.5d
Short vol30%
Last earningsAug 5, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
+46%
above
RSI (14)
81
overbought
MACD trend
Positive
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+62%
trailing
6-month return
+52%
trailing
YTD return
+3%
this year
Relative strength
+38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +17 funds added
Insider flow
Accumulating
Net +$68.8K over 90 days · 0% sells
Short interest
Falling
1.50% of float · ▼ -0.4% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
111 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
86%
expanding
EPS growth
+28%
Y/Y
Free cash flow
$-29.9M
Balance sheet
$51.7M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
full year 2026
Adjusted operating expense
Non-GAAP
$92M – $94M
third quarter
Interventional dry eye revenue
$3M
Prior guidance
period ended
· from the 8-K filed Jan 13, 2026
Total revenue
· fourth quarter 2025
$20.3M – $20.4M
Dry Eye revenues
· fourth quarter 2025
$700,000
Total revenue
· full year 2025
$77.3M – $77.4M
Surgical Glaucoma revenues
· fourth quarter 2025
$19.6M – $19.7M
Surgical Glaucoma revenues
· full year 2025
$75.6M – $75.7M
Dry Eye revenues
· full year 2025
$1.6M
Guided vs delivered
· last 2 settled
Revenue
full year 2025
guided $76M – $78M
$77.36M
In line
Revenue
full year 2024
guided $81M – $85M
$79.87M
Miss −3.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
+46%
Bullish
RSI (14)
81
Bearish
MACD trend
Positive
Bullish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +17 funds added
Insider flow
Accumulating
Net +$68.8K over 90 days · 0% sells
Short interest
Falling
1.50% of float · ▼ -0.4% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
111 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $8 · 84%
Range high $9
vs 200-day avg +44%
vs 50-day avg +46%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Operating Expenses non-GAAP | 43.49M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Dry Eye active customers | 176 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Dry Eye lid treatment units sold | 3,091 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Glaucoma active customers | 1,214 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Glaucoma gross margin | 89.9% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Dry Eye gross margin | 72% | the first quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGHT
this stock
Sight Sciences, Inc.
|
$448.42M | +2.6% | -3.1% | — | 1.5% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGHT | +9.0% | +61.8% | +51.9% | +54.8% | +2.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +8.6% | +57.4% | +38.1% | +50.8% | -11.2% |
Key facts
CIK
1531177
CUSIP
82657M105
13F (30d)
108 filings
108 filers
Visit website
Investor relations